IRVINGTON, NY -- (MARKET WIRE) -- October 12, 2006 -- Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA), a medical device company focused on the design and development of MelaFind®, a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma, today announced that the U.S. Food and Drug Administration (FDA) has informed EOS that, when submitted, the MelaFind Premarket Approval (PMA) application will receive expedited review processing. Expedited review means that upon filing a PMA with the FDA, it is placed at the beginning of the FDA's review queue and receives additional review resources.
